| Gemcitabine: current role and future options in the treatment of ovarian cancer. | |
| | |
MedLine Citation:
|
PMID: 14585485 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Epithelial ovarian cancer is the gynecological malignancy with the highest mortality. The standard therapeutic approach for patients with advanced-stage epithelial ovarian cancer has been cytoreductive surgery followed by combination chemotherapy. Despite improvements in outcome via carboplatin/paclitaxel based chemotherapy, 30% of patients with ovarian cancer fail to respond to primary therapy; moreover, 55-75% of responders relapse within 1 or 2 years from the end of primary treatment and die of the disease within 5 years from their initial diagnosis. Gemcitabine has been shown to be active as a single agent and in combination with other drugs, including carboplatin and paclitaxel, in the treatment of patients with recurrent ovarian cancer. It is currently under evaluation in new combinations for initial therapy in ovarian cancer patients. |
| | |
Authors:
|
Erika Fruscella; Daniela Gallo; Gabriella Ferrandina; Giuseppe D'Agostino; Giovanni Scambia |
Related Documents
:
|
15870565 - Fertility preservation options for female patients with malignancies. 19724865 - Identification of candidate epigenetic biomarkers for ovarian cancer detection. 3108215 - Relationship between westernization of dietary habits and mortality from breast and ova... 7967985 - Parity, age at first childbirth, and risk of ovarian cancer. 9033225 - Seasonal variation and weather effects on road traffic accidents in riyadh city. 20129485 - The role of prostacyclin in lung cancer. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Critical reviews in oncology/hematology Volume: 48 ISSN: 1040-8428 ISO Abbreviation: Crit. Rev. Oncol. Hematol. Publication Date: 2003 Oct |
Date Detail:
|
Created Date: 2003-10-30 Completed Date: 2004-07-08 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 8916049 Medline TA: Crit Rev Oncol Hematol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 81-8 Citation Subset: IM |
Affiliation:
|
Department of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo A. Gemelli, 8, 00168 Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
therapeutic use Deoxycytidine / analogs & derivatives*, therapeutic use* Female Humans Ovarian Neoplasms / drug therapy* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
103882-84-4/gemcitabine; 951-77-9/Deoxycytidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Venous thromboembolism and cancer: new issues for an old topic.
Next Document: Follow-up care of breast cancer survivors.